Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Be3b47a20dd58b51c7efc4eb0fb3a4aea> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Be3b47a20dd58b51c7efc4eb0fb3a4aea NCIT_P378 "NCI" @default.
- Be3b47a20dd58b51c7efc4eb0fb3a4aea type Axiom @default.
- Be3b47a20dd58b51c7efc4eb0fb3a4aea annotatedProperty IAO_0000115 @default.
- Be3b47a20dd58b51c7efc4eb0fb3a4aea annotatedSource NCIT_C77886 @default.
- Be3b47a20dd58b51c7efc4eb0fb3a4aea annotatedTarget "A fully human, second-generation, nonfucosylated monoclonal antibody directed against the cell surface receptor CD30 with potential immunomodulating and antineoplastic activities. Anti-CD30 monoclonal antibody MDX-1401 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas. Compared to conventional antibodies, deletion of fucose molecules on the antibody backbone, as is done in MDX-1401, may result in an increased affinity for Fc receptors and an enhanced antibody-dependent cellular cytotoxicity (ADCC)." @default.